These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 10686311)

  • 41. Mofetil mycophenolate in renal transplantation.
    Pretagostini R; Rossi M; Berloco P; Colonnello M; Bruzzone P; Peritore D; Lonardo MT; Cortesini R
    Transplant Proc; 2001; 33(1-2):1082-3. PubMed ID: 11267200
    [No Abstract]   [Full Text] [Related]  

  • 42. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation.
    Bruce DS; Woodle ES; Newell KA; Millis JM; Cronin DC; Loss GE; Grewal HP; Siegel CT; Pellar S; Josephson MA; Thistlethwaite JR
    Transplant Proc; 1998 Jun; 30(4):1538-40. PubMed ID: 9636625
    [No Abstract]   [Full Text] [Related]  

  • 43. Induction treatment with mycophenolate mofetil, cyclosporine, and low-dose steroids with subsequent early withdrawal in renal transplant patients: results of the Spanish Group. Spanish Group of the CellCept Study.
    Puig i Marí JM
    Transplant Proc; 1999 Sep; 31(6):2256-8. PubMed ID: 10500566
    [No Abstract]   [Full Text] [Related]  

  • 44. Immunosuppression using tacrolimus/mycophenolate versus neoral/mycophenolate following kidney transplantation: a single-center experience.
    Urbizu JM; Amenabar JJ; Gomez-Ullate P; Zarraga S; Lampreabe I
    Transplant Proc; 2002 Feb; 34(1):87-8. PubMed ID: 11959197
    [No Abstract]   [Full Text] [Related]  

  • 45. Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation.
    Cantarovich D; Giral-Classe M; Hourmant M; Dantal J; Blancho G; Lerat L; Moreau A; Soulillou JP
    Nephrol Dial Transplant; 2000 Oct; 15(10):1673-6. PubMed ID: 11007839
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients.
    Fischer L; Sterneck M; Gahlemann CG; Malago M; Rogiers X; Broelsch CE
    Transplant Proc; 2000 Nov; 32(7):2125-7. PubMed ID: 11120098
    [No Abstract]   [Full Text] [Related]  

  • 47. ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis.
    Kumar MS; Cahill K; Kumar AM; Panigrahi D; Seirka D; Singleton R; al-Abdullah IH; Laskow DA
    Transplant Proc; 1998 Jun; 30(4):1351-2. PubMed ID: 9636549
    [No Abstract]   [Full Text] [Related]  

  • 48. Mycophenolate mofetil in ongoing chronic kidney allograft dysfunction.
    Senn B; Rochat P; Schwarzkopf AK; Weinreich T; Binswanger U
    Transplant Proc; 1998 Dec; 30(8):4075-6. PubMed ID: 9865301
    [No Abstract]   [Full Text] [Related]  

  • 49. Results of kidney transplantation in patients receiving MMF- or MMF and basiliximab-containing immunosuppression.
    Tojimbara T; Nakajima I; Sato S; Nakamura M; Kawase T; Kai K; Tsuda S; Kudo S; Fuchinoue S; Teraoka S
    Transplant Proc; 2004 Sep; 36(7):2087-9. PubMed ID: 15518755
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tacrolimus-based immunosuppression in pediatric renal transplantation.
    Jordan ML; Shapiro R; Scantlebury V; Vivas C; Ellis D; Lombardozzi-Lane S; Starzl TE
    Transplant Proc; 1999 Nov; 31(7A):29S-30S. PubMed ID: 10576039
    [No Abstract]   [Full Text] [Related]  

  • 51. The treatment of chronic rejection with mycophenolate mofetil versus azathioprine in kidney transplantation.
    Jirasiritham S; Sumethkul V; Mavichak V; Chalermsanyakorn P
    Transplant Proc; 2000 Nov; 32(7):2040-2. PubMed ID: 11120057
    [No Abstract]   [Full Text] [Related]  

  • 52. Effect of mycophenolate mofetil on the prevention of acute renal allograft rejection.
    Miladipour AH; Ghods AJ; Nejadgashti H
    Transplant Proc; 2002 Sep; 34(6):2089-90. PubMed ID: 12270325
    [No Abstract]   [Full Text] [Related]  

  • 53. Prospective study of mycophenolate mofetil for the prevention of acute rejection in living donor renal allograft recipients.
    Park K; Kim SI; Moon JI; Kim YS; Kim MS
    Transplant Proc; 1998 Nov; 30(7):3575. PubMed ID: 9838565
    [No Abstract]   [Full Text] [Related]  

  • 54. Long-term experience with mycofenolate mofetil in the prevention of renal allograft rejection.
    Behrend M; Lueck R; Pichlmayr R
    Transplant Proc; 1997 Nov; 29(7):2927-9. PubMed ID: 9365617
    [No Abstract]   [Full Text] [Related]  

  • 55. Current advantage of FK 506 in cadaveric kidney transplantation.
    Ciancio G; Rosen A; Loreto-Grand B; Burke G; Siquijor A; Luque C; Esquenazi V; Miller J
    Transplant Proc; 1996 Apr; 28(2):1000-1. PubMed ID: 8623207
    [No Abstract]   [Full Text] [Related]  

  • 56. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression.
    Gralla J; Wiseman AC
    Transplantation; 2010 Sep; 90(6):639-44. PubMed ID: 20595929
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Double versus single renal allografts from aged donors.
    Andrés A; Morales JM; Herrero JC; Praga M; Morales E; Hernández E; Ortuño T; Rodício JL; Martínez MA; Usera G; Díaz R; Polo G; Aguirre F; Leiva O
    Transplantation; 2000 May; 69(10):2060-6. PubMed ID: 10852597
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab.
    Folkmane I; Bicans J; Amerika D; Chapenko S; Murovska M; Rosentals R
    Transplant Proc; 2001; 33(7-8):3209-10. PubMed ID: 11750377
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.